Patents by Inventor Andrew B. West

Andrew B. West has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazolopyridazine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
    Patent number: 9187484
    Abstract: Provided are novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors. Examples of LRRK2 kinase inhibitors are compounds of the formula: or derivatives thereof. An example is 1-(piperidin-1-yl)-2-((3-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)thio)butan-1-one. Particular uses include treating neurodegenerative diseases, cancer, autoimmune diseases and leprosy.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: November 17, 2015
    Assignees: Southern Research Institute, The UAB Research Foundation
    Inventors: Robert A. Galemmo, Jr., Andrew B. West, Joseph A. Maddry, Subramaniam Ananthan, Ashish Kumar Pathak, Jacob Valiyaveettil
  • LRRK-2-Mediated Neuronal Toxicity
    Publication number: 20150018301
    Abstract: Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration were identified. The presently disclosed subject matter establishes that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for treating Parkinson's disease.
    Type: Application
    Filed: November 8, 2010
    Publication date: January 15, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Byoung Dae Lee, Ted M. Dawson, Valina L. Dawson, Andrew B. West, Howard Federoff
  • TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF
    Publication number: 20130296298
    Abstract: The present invention provides novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors.
    Type: Application
    Filed: May 2, 2013
    Publication date: November 7, 2013
    Applicants: THE UAB RESEARCH FOUNDATION, Southern Research Institute
    Inventors: Robert A. Galemmo, JR., Andrew B. West, Joseph A. Maddry, Subramaniam Ananthan, Ashish Kumar Pathak, Jacob Valiyaveettil